Phaseline

Targets › PTH1R

PTH1R (Parathyroid hormone/parathyroid hormone-related peptide receptor): drug programs, companies and trials

8 programs from 8 companies in 9 trials: 4 Phase 4, 3 Phase 3, 1 Phase 2, 1 Phase 1; Metabolic and endocrine, Other, Genitourinary; next expected readout Dec 2026.

G protein-coupled receptor for parathyroid hormone (PTH) and for parathyroid hormone-related peptide (PTHLH). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (cAMP). (UniProt, Q03431)

Open in Phaseline: the race on PTH1R, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Hospital for Special Surgery, New YorkAbaloparatide
Parathyroid hormone receptor agonist
PTH1RPhase 4Osteoporosis, Postmenopausal; Spinal FusionDec 2026
Madhumathi RaoTeriparatide
Parathyroid hormone receptor agonist
PTH1RPhase 4Age-Related OsteoporosisJan 2027
Ditte HansenTeriparatide
Parathyroid hormone receptor agonist
PTH1RPhase 4Adynamic Bone DiseaseSep 2027
Massachusetts General HospitalTeriparatide
Parathyroid hormone receptor agonist
PTH1RPhase 4Osteoporosis, PostmenopausalNov 2027
Ascendis Pharma Bone DiseasesPalopegteriparatide
Parathyroid hormone receptor agonist
PTH1RPhase 3HypoparathyroidismJun 2027
AstraZenecaeneboparatide
PTH1 receptor agonist (parathyroid hormone analog)
PTH1RPhase 3Chronic HypoparathyroidismJun 2027
Ascendis PharmaPalopegteriparatide
Parathyroid hormone receptor agonist
PTH1RPhase 3HypoparathyroidismAug 2027
National Institute of Dental and Craniofacial Research (NIDCR)PTH-IA
PTH1R inverse agonist, decreases proportion of mutant PTH1R receptors in active-state conf
PTH1RPhase 1Jansen's Metaphyseal ChondrodysplasiaJun 2029

Conditions

Osteoporosis, Postmenopausal (2) Hypoparathyroidism (2) Spinal Fusion (1) Adynamic Bone Disease (1) Jansen's Metaphyseal Chondrodysplasia (1) Age-Related Osteoporosis (1) Chronic Hypoparathyroidism (1)

Modalities

protein or peptide (4), mixed (3), small molecule (1)

Companies

Hospital for Special Surgery, New York (1) Ascendis Pharma Bone Diseases (1) Ascendis Pharma (1) Ditte Hansen (1) National Institute of Dental and Craniofacial Research (NIDCR) (1) Madhumathi Rao (1) Massachusetts General Hospital (1) AstraZeneca (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.